ERJ Podcast March 2025: Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis

ERJ Podcast March 2025: Generalisability of p...

Up next

ERJ Podcast February 2026: Addressing the global challenges of COPD and asthma

As part of the February issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews David Halpin (University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK) about hi ...  Show more

ERS Monograph: Chronic Cough

"Even now, many patients remain misunderstood and mislabelled by their clinician and their family, and even by our society." In this instalment of the ERS Monograph podcast, Guido Marchi (Early Career Member representative for the Monograph) meets with the Guest Editors of Chroni ...  Show more

Recommended Episodes

Pulmonary | Pulmonary Hypertension Drugs
The Medbullets Step 2 & 3 Podcast

In this episode, we review the high-yield topic of ⁠⁠⁠<a href="https://step2.medbullets.com/pulmona ...

  Show more

Pulmonary Hypertension
The Rx Bricks Podcast

Normal blood pressure keeps us alive. It’s the force that moves blood throughout our circulatory system, ensuring that oxygen and nutrients reach our organs and tissues and that waste products are eliminated. When we hear the word hypertension—high blood pressure—we know this ...

  Show more

S6 E9: Interview with Dr Stephen Bradley on CXR rates in GP & lung cancer; orthostatic HYPERtension; overactive bladder tests
NB Hot Topics Podcast

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we are joined by Dr Stephen Bradley, lead author of a new paper published in the BJGP looking at rates of CXR use in general practice and how this influences lung cancer stage at diagnosis and ...  Show more

Respiratory | Pulmonary Hypertension Drugs
The Medbullets Step 1 Podcast

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ...  Show more